Leukotrienes, a potential target for Covid-19

Prostaglandins Leukot Essent Fatty Acids. 2020 Oct;161:102174. doi: 10.1016/j.plefa.2020.102174. Epub 2020 Sep 17.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetates / therapeutic use
  • Adrenal Cortex Hormones / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Arachidonic Acid / metabolism
  • Betacoronavirus / drug effects
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity
  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / metabolism
  • Coronavirus Infections / virology
  • Cytokine Release Syndrome / immunology
  • Cytokine Release Syndrome / metabolism
  • Cytokine Release Syndrome / prevention & control*
  • Cytokine Release Syndrome / virology
  • Humans
  • Hydroxyurea / analogs & derivatives
  • Hydroxyurea / therapeutic use
  • Immunologic Factors / therapeutic use*
  • Leukotrienes / metabolism*
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / metabolism
  • Pneumonia, Viral / virology
  • Quinolines / therapeutic use
  • SARS-CoV-2
  • Severity of Illness Index
  • Tosyl Compounds / therapeutic use

Substances

  • Acetates
  • Adrenal Cortex Hormones
  • Anti-Inflammatory Agents, Non-Steroidal
  • Immunologic Factors
  • Leukotrienes
  • Quinolines
  • Tosyl Compounds
  • Arachidonic Acid
  • montelukast
  • zileuton
  • Hydroxyurea
  • zafirlukast